Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia. / Elabi, Osama F.; Pass, Rachel; Sormonta, Irene; Nolbrant, Sara; Drummond, Nicola; Kirkeby, Agnete; Kunath, Tilo; Parmar, Malin; Lane, Emma L.

In: Journal of Parkinson's Disease, Vol. 12, No. 6, 2022, p. 1881-1896.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Elabi, OF, Pass, R, Sormonta, I, Nolbrant, S, Drummond, N, Kirkeby, A, Kunath, T, Parmar, M & Lane, EL 2022, 'Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia', Journal of Parkinson's Disease, vol. 12, no. 6, pp. 1881-1896. https://doi.org/10.3233/JPD-212920

APA

Elabi, O. F., Pass, R., Sormonta, I., Nolbrant, S., Drummond, N., Kirkeby, A., Kunath, T., Parmar, M., & Lane, E. L. (2022). Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia. Journal of Parkinson's Disease, 12(6), 1881-1896. https://doi.org/10.3233/JPD-212920

Vancouver

Elabi OF, Pass R, Sormonta I, Nolbrant S, Drummond N, Kirkeby A et al. Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia. Journal of Parkinson's Disease. 2022;12(6):1881-1896. https://doi.org/10.3233/JPD-212920

Author

Elabi, Osama F. ; Pass, Rachel ; Sormonta, Irene ; Nolbrant, Sara ; Drummond, Nicola ; Kirkeby, Agnete ; Kunath, Tilo ; Parmar, Malin ; Lane, Emma L. / Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia. In: Journal of Parkinson's Disease. 2022 ; Vol. 12, No. 6. pp. 1881-1896.

Bibtex

@article{e9147e8ef2dd4c8ca1298cccce531ae5,
title = "Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia",
abstract = "BACKGROUND: First-in-human studies to test the efficacy and safety of human embryonic stem cells (hESC)-derived dopaminergic cells in the treatment of Parkinson's disease (PD) are imminent. Pre-clinical studies using hESC-derived dopamine neuron transplants in rat models have indicated that the benefits parallel those shown with fetal tissue but have thus far failed to consider how ongoing L-DOPA administration might impact on the graft. OBJECTIVE: To determine whether L-DOPA impacts on survival and functional recovery following grafting of hESC-derived dopaminergic neurons. METHODS: Unilateral 6-OHDA lesioned rats were administered with either saline or L-DOPA prior to, and for 18 weeks following surgical implantation of dopaminergic neural progenitors derived from RC17 hESCs according to two distinct protocols in independent laboratories. RESULTS: Grafts from both protocols elicited reduction in amphetamine-induced rotations. Reduced L-DOPA-induced dyskinesia preceded the improvement in amphetamine-induced rotations. Furthermore, L-DOPA had no effect on overall survival (HuNu) or dopaminergic neuron content of the graft (TH positive cells) but did lead to an increase in the number of GIRK2 positive neurons. CONCLUSION: Critically, we found that L-DOPA was not detrimental to graft function, potentially enhancing graft maturation and promoting an A9 phenotype. Early improvement of L-DOPA-induced dyskinesia suggests that grafts may support the handling of exogenously supplied dopamine earlier than improvements in amphetamine-induced behaviours indicate. Given that one of the protocols will be employed in the production of cells for the European STEM-PD clinical trial, this is vital information for the management of patients and achieving optimal outcomes following transplantation of hESC-derived grafts for PD.",
keywords = "6-OHDA lesioned rat, abnormal involuntary movements, human embryonic stem cells, L-dopa-induced dyskinesia, Parkinson{\textquoteright}s disease, transplantation",
author = "Elabi, {Osama F.} and Rachel Pass and Irene Sormonta and Sara Nolbrant and Nicola Drummond and Agnete Kirkeby and Tilo Kunath and Malin Parmar and Lane, {Emma L.}",
year = "2022",
doi = "10.3233/JPD-212920",
language = "English",
volume = "12",
pages = "1881--1896",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "I O S Press",
number = "6",

}

RIS

TY - JOUR

T1 - Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia

AU - Elabi, Osama F.

AU - Pass, Rachel

AU - Sormonta, Irene

AU - Nolbrant, Sara

AU - Drummond, Nicola

AU - Kirkeby, Agnete

AU - Kunath, Tilo

AU - Parmar, Malin

AU - Lane, Emma L.

PY - 2022

Y1 - 2022

N2 - BACKGROUND: First-in-human studies to test the efficacy and safety of human embryonic stem cells (hESC)-derived dopaminergic cells in the treatment of Parkinson's disease (PD) are imminent. Pre-clinical studies using hESC-derived dopamine neuron transplants in rat models have indicated that the benefits parallel those shown with fetal tissue but have thus far failed to consider how ongoing L-DOPA administration might impact on the graft. OBJECTIVE: To determine whether L-DOPA impacts on survival and functional recovery following grafting of hESC-derived dopaminergic neurons. METHODS: Unilateral 6-OHDA lesioned rats were administered with either saline or L-DOPA prior to, and for 18 weeks following surgical implantation of dopaminergic neural progenitors derived from RC17 hESCs according to two distinct protocols in independent laboratories. RESULTS: Grafts from both protocols elicited reduction in amphetamine-induced rotations. Reduced L-DOPA-induced dyskinesia preceded the improvement in amphetamine-induced rotations. Furthermore, L-DOPA had no effect on overall survival (HuNu) or dopaminergic neuron content of the graft (TH positive cells) but did lead to an increase in the number of GIRK2 positive neurons. CONCLUSION: Critically, we found that L-DOPA was not detrimental to graft function, potentially enhancing graft maturation and promoting an A9 phenotype. Early improvement of L-DOPA-induced dyskinesia suggests that grafts may support the handling of exogenously supplied dopamine earlier than improvements in amphetamine-induced behaviours indicate. Given that one of the protocols will be employed in the production of cells for the European STEM-PD clinical trial, this is vital information for the management of patients and achieving optimal outcomes following transplantation of hESC-derived grafts for PD.

AB - BACKGROUND: First-in-human studies to test the efficacy and safety of human embryonic stem cells (hESC)-derived dopaminergic cells in the treatment of Parkinson's disease (PD) are imminent. Pre-clinical studies using hESC-derived dopamine neuron transplants in rat models have indicated that the benefits parallel those shown with fetal tissue but have thus far failed to consider how ongoing L-DOPA administration might impact on the graft. OBJECTIVE: To determine whether L-DOPA impacts on survival and functional recovery following grafting of hESC-derived dopaminergic neurons. METHODS: Unilateral 6-OHDA lesioned rats were administered with either saline or L-DOPA prior to, and for 18 weeks following surgical implantation of dopaminergic neural progenitors derived from RC17 hESCs according to two distinct protocols in independent laboratories. RESULTS: Grafts from both protocols elicited reduction in amphetamine-induced rotations. Reduced L-DOPA-induced dyskinesia preceded the improvement in amphetamine-induced rotations. Furthermore, L-DOPA had no effect on overall survival (HuNu) or dopaminergic neuron content of the graft (TH positive cells) but did lead to an increase in the number of GIRK2 positive neurons. CONCLUSION: Critically, we found that L-DOPA was not detrimental to graft function, potentially enhancing graft maturation and promoting an A9 phenotype. Early improvement of L-DOPA-induced dyskinesia suggests that grafts may support the handling of exogenously supplied dopamine earlier than improvements in amphetamine-induced behaviours indicate. Given that one of the protocols will be employed in the production of cells for the European STEM-PD clinical trial, this is vital information for the management of patients and achieving optimal outcomes following transplantation of hESC-derived grafts for PD.

KW - 6-OHDA lesioned rat

KW - abnormal involuntary movements

KW - human embryonic stem cells

KW - L-dopa-induced dyskinesia

KW - Parkinson’s disease

KW - transplantation

U2 - 10.3233/JPD-212920

DO - 10.3233/JPD-212920

M3 - Journal article

C2 - 35466951

AN - SCOPUS:85137158954

VL - 12

SP - 1881

EP - 1896

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 6

ER -

ID: 319247653